BioDelivery Progresses with Clonidine Late-Stage Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 5:00PM CDT
BioDelivery (BDSI) announced that it has completed patient enrolment for its phase III RHAPSODY study on clonidine topical gel.
Coronado Falls on TSO Study Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 10:20AM CDT
Coronado (CNDO) announced disappointing top-line results from a pilot study on TSO.
Brain Injury - Pipeline Review, H1 2014
M2 - Fri Jun 27, 5:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6zjvn6/brain_injury) has announced the addition of the "Brain Injury - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Injury and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Brain Injury - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Brain Injury pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Biogen Idec Inc. - Acorda Therapeutics, Inc. - Chiesi Farmaceutici SpA - TetraLogic Pharmaceuticals - Virogenomics, Inc. - Faron Pharmaceuticals Oy For more information visit http://www.researchandmarkets.com/research/6z...ain_injury
Auxilium/Sobi's Xiapex Filed for Label Expansion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 4:00PM CDT
Auxilium (AUXL) announced that Sobi has filed for an extension of the label for Xiapex in the EU to include the indication of Peyronie's disease.
Bristol-Myers Up on Nivolumab News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 9:45AM CDT
Bristol-Myers' (BMY) nivolumab performed very well in a late-stage study.
Prothena Corporation (PRTA) Falls: Stock Goes Down 5.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 7:43AM CDT
Shares of Prothena Corporation (PRTA) fell over 5% on the day. This continues the most recent downtrend for PRTA, as the stock is down nearly 12% since Jun 18. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future.
Isis Pharma Gets $1M Milestone Payment from Glaxo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 5:10PM CDT
Isis Pharmaceuticals, Inc. (ISIS) earned a $1 million milestone payment from GlaxoSmithKline pertaining to the advancement of ISIS-TTR in phase II/III study.
Ligand Pharma-TG Therapeutics Collaborate on IRAK4 Inhibitors - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 3:30PM CDT
Ligand Pharmaceuticals Inc. (LGND) inked a deal with TG Therapeutics, Inc. to develop and commercialize Ligand's IRAK-4 inhibitors.
British Columbia to Reimburse TECFIDERA(TM), a First-Line Oral Treatment for Multiple Sclerosis
CNW Group - Wed Jun 25, 10:00AM CDT
Biogen Idec Canada announces today that TECFIDERATM (dimethyl fumarate) is now available for reimbursement in British Columbia (B.C.) through B.C. PharmaCare. TECFIDERATM is a first-line oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). TECFIDERATM is indicated as monotherapy for the treatment of RRMS to reduce the frequency of clinical exacerbations and to delay the progression of disability.(1)
Critical Alerts For Vertex Pharmaceuticals, Dollar Tree, Avis, Ryder, and Biogen Released By InvestorsObserver
PR Newswire - Wed Jun 25, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for VRTX, DLTR, CAR, R, and BIIB.
XenoPort's XP23829 in Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 3:52PM CDT
XenoPort, Inc. (XNPT) has commenced a phase II study on XP23829 for moderate-to-severe chronic plaque-type psoriasis.
Insider Trading Alert - BIIB, FDS And GCO Traded By Insiders
at The Street - Tue Jun 24, 9:45AM CDT
Stocks with insider trader activity include BIIB, FDS and GCO
Stocks with Upgraded Broker Ratings - Screen of the Week
Kevin Matras - Zacks Investment Research - Tue Jun 24, 3:05AM CDT
Stocks with Upgraded Broker Ratings - Screen of the Week
AbbVie, Shire Give Bullish Guidance Amid Buyout Talk
at Investor's Business Daily - Mon Jun 23, 10:24AM CDT
Big pharma AbbVie (ABBV) raised its 2014 earnings guidance Monday, sending the company's stock up 1.5% in morning trading on the stock market. Meanwhile, AbbVie's buyout target Shire (SHPG) detailed its own bullish guidance in explaining to investors...
Trade-Ideas: Biogen Idec (BIIB) Is Today's Momo Momentum Stock
at The Street - Fri Jun 20, 9:32AM CDT
Trade-Ideas LLC identified Biogen Idec (BIIB) as a momo momentum candidate
Global Human Papillomavirus Infections Pipeline Analysis 2014
M2 - Thu Jun 19, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r42gfc/human) has announced the addition of the "Human Papillomavirus Infections Pipeline Analysis" report to their offering. Currently there is significant amount of research being undertaken to study the process of HPV infection causing precancerous changes in normal cells. Also, methods to prevent and manage this situation are also being analyzed. A majority of these studies were previously focusing on cervical cells in women. But in recent years, the realm of research has been extended to other tissues also in which HPV may cause cancer, such as the oropharynx and anus. Also, many organizations are analyzing the use of second-generation preventive vaccines along with therapeutic HPV vaccines, which could possibly prevent the development of cancer among women previously infected with HPV. Such an ideal vaccine strategy would combine a preventive and therapeutic vaccine, which would help in a major way. The mechanism of the HPV vaccines is similar to the other immunizations which help in protecting against viral infections. It has been observed and analyzed that the unique surface components of HPV have the capability to create an antibody response which could possibly protect the human body against infection. These components could thus be used as a basis of the vaccine. There are only 2 HPV vaccines which are currently marketed across the globe. Both these vaccines are prepared using the recombinant technology, which is taken from purified L1 structural proteins which self assemble to form HPV type-specific empty shells or virus-like particles (VLPs). Since there are no therapeutic HPV vaccines available at present which have proved their efficiency in the clinical trials, there is still a lot of work which is required in this field, thus opening a large window of opportunities. There have been some technological advancements in the past 4-5 years. The future is also likely to continue to witness similar technological and medical success in terms of new drugs and efficient vaccines, with the help of adequate funding. Certain developments like a new treatment to reduce transmissibility in drug users and new efforts to strengthen the immune system have the potential to develop further and provide better healthcare services to the patients in the future. Thus, there needs to be more focus being given to increasing the knowledge and awareness about HPV infections and the ways and methods to treat it, either through drugs or through vaccines. Human Papillomavirus Infections Vaccine Pipeline Analysis - Report Highlights: - Human Papillomavirus Vaccine Market Overview - Marketed Drug Profiles & Patent Analysis - Clinical Trial Insight by Phase & Country - Drug Clinical Development Phase: 47 - Suspended & Discontinued Drug Profiles: 46 - Competitive Landscape Companies Mentioned - Advanced Viral Research - BioSphings, - Biogen Idec, - EyeGene, - Helix BioPharma, - Inviragen, - MedImmune, - Merck & Co, - Valeant Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/r42gfc/human
Is This the Next Blockbuster MS Treatment?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Wed Jun 18, 4:30PM CDT
Biogen Idec and its partner AbbVie reported good late stage results for multiple sclerosis drug daclizumab. While some are concerned about the increase in serious infections and a higher relapse rate than its earlier study, it shouldn't stop the...
Biogen/AbbVie Presents Positive Data on Daclizumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 4:03PM CDT
Biogen Idec (BIIB) and partner AbbVie (ABBV) announced positive top-line results from a phase III trial, DECIDE, on pipeline candidate, daclizumab.
Biotech Stock Roundup: HCV Back in Focus - Idenix, Achillion Soar - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 18, 9:33AM CDT
It was about hepatitis C cirus (HCV) treatments and companies last week with the Merck-Idenix acquisition announcement grabbing eyeballs.